$6.08
0.83%
Nasdaq, Fri, Sep 27 2024
ISIN
US72940R1023
Symbol
PSTI
Sector
Industry

Pluristem Therapeutics Inc. Stock price

$6.08
+0.54 9.75% 1M
-0.96 13.62% 6M
+1.44 31.15% YTD
+1.38 29.45% 1Y
-16.08 72.56% 3Y
-24.48 80.10% 5Y
-226.72 97.39% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.05 0.83%
ISIN
US72940R1023
Symbol
PSTI
Sector
Industry

Key metrics

Market capitalization $32.99m
Enterprise Value $37.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 114.18
P/S ratio (TTM) P/S ratio 99.97
P/B ratio (TTM) P/B ratio 339.72
Revenue growth (TTM) Revenue growth 13.59%
Revenue (TTM) Revenue $330.00k
EBIT (operating result TTM) EBIT $-22.16m
Free Cash Flow (TTM) Free Cash Flow $-18.34m
Cash position $30.24m
EPS (TTM) EPS $-3.98
Short interest 1.28%
Show more

Is Pluristem Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Pluristem Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Pluristem Therapeutics Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Pluristem Therapeutics Inc.:

Hold
100%

Financial data from Pluristem Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.33 0.33
14% 14%
100%
- Direct Costs 0.26 0.26
30% 30%
79%
0.07 0.07
188% 188%
21%
- Selling and Administrative Expenses 9.53 9.53
14% 14%
2,888%
- Research and Development Expense 12 12
21% 21%
3,773%
-22 -22
18% 18%
-6,639%
- Depreciation and Amortization 0.25 0.25
31% 31%
76%
EBIT (Operating Income) EBIT -22 -22
19% 19%
-6,715%
Net Profit -21 -21
26% 26%
-6,330%

In millions USD.

Don't miss a Thing! We will send you all news about Pluristem Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Head office United States
CEO Yaky Yanay
Employees 106
Founded 2001
Website www.pluri-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today